HSP90 inhibition is therefore considered a potential therapeutic strategy to ameliorate the ECM dysregulation characteristic of fibrosis and cancer (Cáceres et al. 2018; Dong et al. 2017; Tomcik et al. 2014; Armstrong et al. 2018). This evidence concerns the gene HSP90AA1 and cancer.